Emerging Viral Diseases (EPV)
Émergence des Pathologies Virales (EPV)

France

1 November 2019 - 31 October 2020

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for Emerging Viral Diseases (EPV) published between 1 November 2019 - 31 October 2020 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Research collaboration: Emerging Viral Diseases (EPV) is a research collaboration whose article contributions are accrued to its participating partner institutions.

Note: Articles may be assigned to more than one subject area.

Count Share
2 0.05

Outputs by subject (Share)

Subject Count Share
Life Sciences 2 0.05

Top articles by Altmetric score in current window

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.

Proceedings of the National Academy of Sciences of the United States of America

2020-10-27

1 November 2019 - 31 October 2020

International vs. domestic collaboration by Share

  • 65.49% Domestic
  • 34.51% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.

Participating institutions

Emerging Viral Diseases (EPV) is a research collaboration whose article contributions are accrued to its participating partner institutions below.

Return to institution outputs